274 Participants Needed

Faricimab for Age-Related Macular Degeneration

(CONSTANCE Trial)

Recruiting at 16 trial locations
RS
Overseen ByReference Study ID Number: MR45638 https://forpatients.roche.com/
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

Research Team

CT

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Eligibility Criteria

This trial is for adults with a specific eye condition called neovascular age-related macular degeneration (nAMD) who haven't had previous treatments. They should be able to see at certain levels, have clear eyes for imaging, agree to follow contraception rules, and be generally healthy.

Inclusion Criteria

Agreement to adhere to the contraception requirements described in the protocol
I have untreated AMD-related vision loss with confirmed fluid in my retina.
Overtly healthy as determined by medical evaluation that includes medical history and physical examination
See 2 more

Exclusion Criteria

My vision loss is not due to age-related macular degeneration.
Current vitreous hemorrhage on Day 1
I have a tear in the retina affecting my central vision.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intravitreal 6-mg faricimab administered at up to 24-week intervals

100 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4-8 weeks

Treatment Details

Interventions

  • Faricimab
Trial Overview The study tests Faricimab's effectiveness and safety in treating nAMD over 100 weeks. Participants will receive the drug through an injection into the eye at intervals that could extend up to 24 weeks.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Arm B: Faricimab Modified Treat & Extend RegimenExperimental Treatment1 Intervention
Group II: Arm A: Faricimab Early Treat & Extend RegimenExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security